Biosenic (LTS:0R55) Long-Term Debt : €22.61 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Biosenic Long-Term Debt?

Biosenic's Long-Term Debt for the quarter that ended in Jun. 2024 was €22.61 Mil.

Biosenic's quarterly Long-Term Debt increased from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€15.57 Mil) and increased from Dec. 2023 (€15.57 Mil) to Jun. 2024 (€22.61 Mil).

Biosenic's annual Long-Term Debt increased from Dec. 2021 (€2.27 Mil) to Dec. 2022 (€14.78 Mil) and increased from Dec. 2022 (€14.78 Mil) to Dec. 2023 (€15.57 Mil).

Biosenic Long-Term Debt Historical Data

The historical data trend for Biosenic's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Long-Term Debt Chart

Biosenic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

10.84

11.67

2.27

14.78

15.57

Biosenic Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial															14.55	14.78	-	15.57	22.61

Biosenic (LTS:0R55) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biosenic Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biosenic's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (LTS:0R55) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BT1:Germany BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic Headlines

No Headlines